Full-Time
Posted on 3/20/2024
Biotechnology tools for genomic research
$165k - $223k/yr
Senior
Pleasanton, CA, USA
10x Genomics provides specialized tools for genomic research, focusing on single-cell analysis, spatial gene expression, and immune profiling. Their products, including laboratory equipment and software, help researchers analyze genetic information in detail, which is essential for understanding complex biological systems. Unlike competitors, 10x Genomics emphasizes high-resolution genomic data to support personalized medicine. The company's goal is to empower scientists with the necessary tools to explore the complexities of the human genome.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Pleasanton, California
Founded
2012
Help us improve and share your feedback! Did you find this helpful?
Comprehensive health benefits
Generous time off
Parental leave
Pleasanton-based 10x Genomics laying off 93 local workers.
10x Genomics announces patent litigation settlement agreement with Bruker.
ROCKVILLE, Md., May 5, 2025 /PRNewswire/ -- Psomagen Inc., a multiomics service laboratory serving academic, pharma, biotech, and clinical customers, will join the Billion Cells Project led by the Chan Zuckerberg Initiative (CZI). The Billion Cells Project aims to develop a landmark single-cell dataset of one billion cells that will be used to train new AI models to advance researchers' understanding of cellular behavior and gene function. Psomagen has begun providing services to participating researchers in April. The project includes collaborations with several other technology partners, including Ultima Genomics, 10x Genomics and Scale Biosciences. Su Hong, CEO of Psomagen, says, "This project represents a transformative step in biomedical research, enabling the identification of novel therapeutic targets and guiding drug development with unparalleled precision. By leveraging AI-powered analysis on vast single-cell datasets, we aim to accelerate the discovery of new ways to restore diseased cells to health
Cardillo joins from 10x Genomics, where she served as Vice President of Corporate Communications.
10x Genomics' ATAC-Seq patents found valid and infringedPLEASANTON, Calif., March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences. Through a consent agreement entered on February 25, 2025, in the United States District Court for the District of Delaware, Parse agreed - a week before trial was to start - to a worldwide permanent injunction that prevents it from making, using, selling or offering for sale its planned ATAC and ATAC-Multiome Single Cell products. As part of this consent agreement, Parse admitted that 10x's ATAC-seq patents are valid, enforceable and infringed by Parse's use of ATAC-seq methods and compositions."This development further validates the strength of our broad patent portfolio, which helps protect and preserve the world-class innovation engine at 10x," said Eric S. Whitaker, Chief Legal Officer of 10x Genomics. "We are pleased with this resolution on ATAC as we continue to defend the asserted Brenner patents on appeal."The company's litigation against Parse's gene expression products remains ongoing, with additional asserted patents under appeal. Following entry of the injunction, the trial scheduled for March 2025 concerning 10x's remaining patent infringement claims against Parse has been stayed pending those appeals.10x Genomics is committed to defending its intellectual property and investing in groundbreaking technologies that empower researchers worldwide.About 10x Genomics10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health